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Could androgens be relevant to partly
explain why men have lower life
expectancy than women?
C Mary Schooling1,2
Life expectancy is about 5 years shorter
for men than for women.1 At any given
age, men are more vulnerable than
women to death from most major causes,
including infections, cancer and cardiovas-
cular disease.1 Lifestyle and stress
undoubtedly play the same role in this dis-
parity as in other health disparities, par-
ticularly given historically higher smoking
rates for men than for women. Whether
these factors provide a comprehensive
explanation and actionable targets of
intervention is less clear, particularly as
these factors do not fully explain men’s
cardiovascular disadvantage.2 Here, to
provide another perspective, the sexual
disparity in life expectancy is considered
in the context of an existing well-
established theory from evolutionary
biology. Life history theory suggests that
animals, including humans, employ envir-
onmentally driven strategies to maximise
Darwinian ﬁtness, that is, reproductive
success.3 Optimal strategies for reproduct-
ive success likely differ by sex, because
men may have far more children than
women4 but reproductive costs are far
higher for women. As such, not only does
a strategy aimed at ﬁtness differ from the
public health goal of long and healthy life
but may also have sex-speciﬁc implica-
tions, and so be relevant to the shorter
lifespan in men than in women.
Speciﬁcally, life history strategies may
involve trading off growth or reproduc-
tion against longevity,3 with the role of
less growth well known but suppressing
the reproductive axis may also increase
lifespan;5 and promoting the reproductive
axis may reduce lifespan. For example, a
high-protein diet in mice results in bigger
gonads and shorter life, while a high-
carbohydrate diet results in smaller
gonads and longer life;6 interestingly mice
prefer a higher protein diet.6 In humans,
the reproductive axis in women is
suppressed at menopause, and artiﬁcial
supplementation with reproductive hor-
mones in postmenopausal women is not
beneﬁcial for lifespan.7 In contrast, men
continue to be fertile throughout adult
life; little consideration has been given to
whether lifelong fertility in men relates to
or trades off against lifespan. Given the
shorter lifespan for men than for women,
consideration is given here to how male
reproductive hormones, namely, andro-
gens, affect health in men beyond repro-
duction, and whether androgens could
have any relevance to the sexual disparity
in life expectancy, or any implications for
the prevention and treatment of the
leading causes of mortality.
NON-REPRODUCTIVE EFFECTS OF
ANDROGENS IN MEN
Currently, the non-reproductive effects of
androgens on men’s health is little
researched.8 The published literature also
suffers from citation bias towards studies
putting testosterone in a positive light.9
Observational evidence concerning
endogenous testosterone is difﬁcult to
interpret because the most commonly
measured androgen biomarker, serum tes-
tosterone, falls in men with obesity and
ill-health.10 Observed inverse associations
of serum testosterone with major causes
of mortality, such as cardiovascular
disease, may be confounded in men by
health status and so be difﬁcult to inter-
pret, as the authors of the relevant system-
atic reviews and meta-analyses have been
careful to note.11–13 Other androgen bio-
markers that give observational associa-
tions more similar to results from
randomised controlled trials (RCTs) for
ischaemic heart disease or its risk factors
are rarely reported.14 Similarly, observa-
tionally, androgens do not predict prostate
cancer,15 but genetic studies have
removed doubts about a role for andro-
gens in prostate cancer.16 Observational
evidence concerning exogenous testoster-
one prescription in men is mixed,17–20
and difﬁcult to interpret because of the
possibility of bias by indication and/or
immortal time,21 which may generate
ﬁndings at variance with meta-analysis of
RCTs.20 22–24 The only observational
study of testosterone prescription that
used a self-comparison and a control
exposure is probably the most convincing:
it found, speciﬁcally, that testosterone pre-
scription was associated with a higher risk
of non-fatal myocardial infarction.25
Evidence about the effects of androgens
from RCTs is limited because the US
Institute of Medicine advised, in 2004,
that no large scale trials of testosterone
should be undertaken until beneﬁts over
existing treatments had been established
in small trials.26 Health comparisons
between men with genetically higher or
lower androgens using Mendelian ran-
domisation are limited because androgens
are rarely measured, so few genetic var-
iants reliably determining androgens have
been identiﬁed.27 28
Nevertheless, information about the
role of androgens in men’s health is
slowly emerging. Below, the effects of
androgens on major contributors to global
mortality are considered, including
immune function, cancer, cardiovascular
disease and diabetes. Given the focus on
the effects of androgens, greatest emphasis
is placed on evidence about likely causal
effects from RCTs, Mendelian randomisa-
tion, experiments, natural experiments
and knockout animal models, rather than
observed associations.
Immune function
Androgens are generally understood to
suppress the immune system;29–32 whereas
oestrogen promotes immune response.33
For example, testosterone may inhibit
CD4 T-cell function,30 while androgen
deprivation is associated with enlargement
of the thymus, which promotes immune
function.29 Experiments in rodents
suggest androgens are pro-inﬂammatory
and delay wound healing.34 35
Men tend to be more vulnerable to
infections than women.33 36 37 Lifestyle
undoubtedly plays a part. However, the
male vulnerability is most evident at ages
when sexual dimorphism in sex hormones
is greatest, those being, early infancy,
puberty and young adult life, and includes
periods, such as early infancy, when life-
style choices are unlikely to differ by
sex.37 Male disadvantage is less evident
for infections where a pathological
immune response occurs.37
On the other hand, androgens may have
the beneﬁt of suppressing autoimmune
responses,29–31 consistent with men being
less vulnerable to autoimmune diseases
than women,29 31 with the difference
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emerging at puberty. Androgen administra-
tion has shown some promise in trials as a
treatment for rheumatoid arthritis.38 39
Whether biological treatments for auto-
immune diseases, such as tumour necrosis
factor-α inhibitors, operate via a similar
mechanism, is unknown.
Cancer
Given androgens’ suppressive effects on
immune function,29–32 androgens are
thought to play a role not only in prostate
and testis cancer, but also in cancer more
generally,29 although evidence in men is
scarce. Based on androgen knockout
models, androgens could play a permissive
role in several cancers with a male pre-
pondrance,40 including cancer of the
bladder,41 kidney,42 liver43 and lung,44 as
well as, perhaps, of the esophagus45 and
colorectum.46 Castration protects male
rats against colonic adenomas.46 Whether
androgens contribute to men’s vulnerabil-
ity to cancer, and whether cancers with
male predominance share features, has
not been comprehensively investigated.
Androgens’ role in immune function also
raises questions about other major chronic
diseases with an inﬂammatory compo-
nent47 48 to which men are more vulner-
able, such as cardiovascular disease.
Cardiovascular disease
Men have higher cardiovascular disease
mortality rates than women,49 particularly
at the period in life, early adulthood, when
male hormones are highest.49 50 However,
haemorrhagic stroke mortality rates differ
little by sex,51 suggesting that the relevant
causative factor underlying men’s cardio-
vascular disadvantage is speciﬁc to pro-
cesses that drive non-haemorrhagic forms
of cardiovascular disease, such as ischae-
mia, thrombosis, embolism and aneurysm.
Notably, androgens may raise clotting
factors, such as thromboxane.52 53
Currently, at the same level of the
major risk factors for atherosclerotic car-
diovascular disease, speciﬁcally, age,
smoking, low-density lipoprotien (LDL)-
cholesterol, high-density lipoprotein
(HDL)-cholesterol, blood pressure and
diabetes, validated risk prediction models
give substantially higher absolute risk for
men than for women.54 Although meno-
pause precedes an increase in ischaemic
heart disease rates for women,55 RCTs
have shown that oestrogen does not
protect against cardiovascular disease in
either men56 or women.7 Recent promo-
tion of highly proﬁtable testosterone to
older men as an antidote to ageing has led
to warnings about the cardiovascular risk
of testosterone from regulators. In June
2014, the US Food and Drug
Administration (FDA) added a warning
about venous blood clots to the testoster-
one product label.57 In July 2014, Health
Canada warned about “serious and pos-
sible life-threatening heart and blood
vessel problems such as heart attack,
stroke, blood clot in the lungs or legs; and
increased or irregular heart rate with the
use of testosterone replacement pro-
ducts”.58 The European Medicines
Agency was less clear in November
2104,59 but advised that testosterone
should be restricted to men with patho-
logical hypogonadism.59 In March 2015,
the US FDA warned about “the possible
increased risk of heart attacks and strokes
associated with testosterone use” and
required a label change.60 Sales of testos-
terone are already falling in the USA61
and litigation against pharmaceutical com-
panies is underway.62
These warnings from regulators about
the cardiovascular risk of testoster-
one57 58 60 suggest that substantially
higher androgens in men than women
could underlie higher cardiovascular
disease mortality rates in men than in
women, although any adverse effects of
exogenous androgens in unhealthy older
men57 58 60 might not translate to
endogenous androgens in healthy men. In
addition, few androgen-related genetic
variants have been found in genome-wide
association studies of cardiovascular
disease. However, few such studies are
sex-speciﬁc, few androgen related genetic
variants have been identiﬁed27 28 and
many genetic variants are of unknown
function, so this may be absence of evi-
dence rather than evidence of absence.
The known effects of testosterone
administration in men from meta-analyses
of RCTs, include lower HDL-choles-
terol,63 higher haemoglobin,63 lower adi-
ponectin64 and higher risk of venous
thrombosis.22 Some of these changes also
take place in boys at puberty under the
inﬂuence of endogenous testosterone,65
suggesting similar effects of exogenous
and endogenous testosterone. Mendelian
randomisation studies also suggest
endogenous testosterone lowers HDL-
cholesterol66 as well as possibly raising
heart rate,67 consistent with the warning
from Health Canada, and again suggesting
similar effects of endogenous and exogen-
ous testosterone. Most systematic reviews
and meta-analyses of RCTs have shown
non-signiﬁcantly higher risk of cardiovas-
cular events on testosterone,68–71 but are
underpowered, partly because of incom-
plete event reporting in the underlying
RCTs,70 and, in one meta-analysis, a
numerical error (reporting on 308 instead
of 485 men).69 Notably, the most recent
trial of testosterone found 12 major
adverse cardiovascular events among 155
men in the treatment arm and 4 among
151 men in the placebo arm, OR 3.08,
95% CI 0.97 to 9.79.72 Men with lower
endogenous testosterone due to legal cas-
tration have relatively lower rates of spe-
ciﬁcally myocardial infarction.73 Similarly,
men with lifelong low testosterone due to
Klinefelter’s syndrome have low rates of
ischaemic heart disease,74 despite well-
known vulnerability to diabetes.75
Diabetes
Diabetes is a strong, well-established risk
factor for cardiovascular disease, although
sex differences in diabetes rates are minor
and inconsistent.76 RCTs suggest andro-
gens improve glucose metabolism,77
perhaps through building muscle mass,
which is a sink for glucose disposal.
Whether treatments for diabetes operate
by raising androgens has rarely been
assessed. However, insulin may raise
androgens,78 which could be relevant to
the difference in magnitude between
observed and causal estimates for the
association of diabetes with cardiovascular
disease.79
ENVIRONMENTAL DRIVERS OF
ANDROGENS
Despite the potential beneﬁts of androgens
for some autoimmune diseases and dia-
betes, consideration of the possibility that
androgens could have a role in chronic dis-
eases with a male preponderance would be
consistent with evolutionary biology and
the newly emerging evidence, as well as
potentially providing aetiological insight
concerning some diseases acknowledged
to be poorly understood.2 Many may feel
that such a perspective would not be
useful in clinical or public health practice
because antiandrogens would be unaccept-
able to men. However, understanding
alone could be valuable. For example,
androgens lowering HDL-cholesterol and
raising cardiovascular disease risk could
underlie the observed inverse association
of HDL-cholesterol with cardiovascular
disease and thereby explain the failure of
HDL-cholesterol raising therapies in
cardiovascular disease.80 Similarly, andro-
gens generating systemic inﬂammation
and raising cardiovascular risk could
explain the failure of several anti-
inﬂammatories.81 Pharmaceutical compan-
ies are investing less in cardiovascular
therapies82 following expensive failures
with lipid modulators and anti-
inﬂammatories, highlighting the need for
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new approaches. Moreover, antiandrogens
are quite widespread and in therapeutic
use. Obesity in men reduces testoster-
one.83 Antiandrogens are used in prostate
cancer. Several therapies for cardiovascular
disease have anti-androgen properties,
such as spironolactone, statins84 and
perhaps digoxin.85 Whether any other
therapies for cardiovascular disease cur-
rently in use or being trialled, such as
diuretics or methotrexate,81 reduce andro-
gens is unknown. Diuretics are thought to
affect sexual function adversely.
Whether androgenic effects could
potentially provide a new classifying prin-
ciple for common modiﬁable environmen-
tal exposures as healthy or otherwise has
rarely been considered. Environmental
drivers of androgens are usually concep-
tualised as xenobiotic endocrine disrup-
tors disrupting androgens, with harmful
effects.86 However, evolutionary biology
would predict that androgens in men
should be sensitive to environmental indi-
cators of breeding conditions, so as to
focus reproductive effort at suitable times
while minimising the risk attached to
extreme masculinity, which may have
been selected against in human history.87
Few common modiﬁable exposures are
known to affect testosterone, apart from
obesity in men, driven by the conversion
of testosterone to oestrogen in fat cells.83
As might be expected, chronic undernutri-
tion reduces testosterone.88 However, the
physiological processes that regulate tes-
tosterone in response to environmental
conditions have not been systematically
investigated. Androgens are sensitive to
environmental inﬂuences, because they
share metabolism and catabolism path-
ways with major drugs, foods and envir-
onmental exposures.89 These catabolism
pathways have been studied in the context
of drug–drug interactions,90 are poly-
morphic,89 and are susceptible to epigen-
etic programming during early life.91
Notably, diclofenac,92 rofecoxib,93 ibu-
profen92 and nicotine,94 all inhibit these
pathways, thereby most likely raising
androgens, and all have unexpected
adverse cardiovascular side effects.95 96
Testing common modiﬁable exposures,
selected according to their role in andro-
gen metabolism or catabolism, for their
effects on androgens in vitro, might
provide a preliminary classiﬁcation of
exposures as potentially adverse or pro-
tective for further investigation in vivo.
CONCLUSION
Considering androgens as potential con-
tributors to major diseases represents a
major paradigm shift that ﬂies in the face
of individual level data from observational
studies. However, in addition to experi-
mental evidence and warnings from regu-
lators, relevant physiological pathways
exist. Androgens suppressing the immune
system could increase vulnerability to
infections and cancer. Androgens increas-
ing clotting could increase vulnerability to
cardiovascular disease. Despite some ben-
eﬁts of androgens for autoimmune dis-
eases and diabetes, men have shorter lives
than women. Current understanding of
major chronic diseases is incomplete.
Surely, we should capitalise on the insight
unexpectedly provided by commercial
promotion of androgens to older men to
rethink the role of androgens, particularly,
in immune function, cancer and cardio-
vascular disease, as potentially providing
an underlying explanatory mechanism
that could address the major sexual dis-
parity in life expectancy, help identify
new speciﬁc targets of intervention,
explain unexpected side effects of com-
monly used drugs and eventually provide
targets for precision medicine.
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